Medicine in the Digital Era: Legal Aspects of the Use of Cell and Gene Therapy in Foreign Countries

The paper examines the experience of legal regulation of the use of cell and gene therapy products, including CAR-T technologies, in the Anglo-Saxon legal system. It is noted that a significant obstacle to the development of CAR-T therapy, as well as cell and gene therapy in general, is the absence in most countries of the world of comprehensive legal regulation of the use of such innovative methods of treating diseases. Currently, this problem is relevant for the Russian Federation, where cell and gene therapy drugs are actively being developed. The paper provides a detailed overview of the main relevant documents from Australia, the United States of America and Canada, analyzes specific cases illustrating successful law enforcement practice, and examines the mechanisms of self-regulation in the area under study. In conclusion, the authors formulate the key problems and ways to improve legal regulation as to cell and gene therapy drugs application in the Russian Federation. The authors recommend that the best practices of these foreign countries be used, taking into account its critical understanding for the development of appropriate regulatory regulation in the Russian Federation and integration associations with its participation.

1. Anagnostou T., Riaz I. B., Hashmi S. K. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis // Lancet Haematol. — 2020. — Vol. 7. — P. 816–826.

2. Anderson W. F. Human gene therapy // Science. — 1992. — Vol. 256. — P. 808–813.

3. Caulfield T. Commentary: the law, unproven CAM and the two-hats fallacy: guest editorial // Focus Altern Complement Ther. — 2012. — Vol. 17(1). — P. 4–8.

4. Chisholm J., von Tigerstrom B., Bedford P., Fradette J., Viswanathan S. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada // Cytotherapy. — 2017. — Vol. 19(12). — P. 1400–11.

5. Marks P., Gottlieb S. Balancing safety and innovation for cell-based regenerative medicine // N. Engl. J. Med. — 2018. — Vol. 378. — P. 954–959.

6. Ogbogu U., Rachul C., Caulfield T. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better? // Regen. Med. — 2013. — Vol. 8(3). — P. 361–9.

7. O’Sullivan G. M., Philips J. G., Mitchell H. J. 20 Years of legislation — how Australia has responded to the challenge of regulating genetically modified organisms in the clinic // Front Med (Lausanne). — 2022. — Vol. 9.

8. Velickovic Z.M, Rasko J. E. Establishing a robust chimeric antigen receptor T-cell therapy program in Australia: the Royal Prince Alfred Hospital experience // Cytotherapy. — 2022. — Vol. 24. — P. 45–48.

9. Viswanathan S., Bubela T. Current practices and reform proposals for the regulation of advanced medicinal products in Canada // Regen. Med. — 2015. — Vol. 10(5). — P. 647–663.